Derek Davis - Zimmer Biomet President
| ZBH Stock | USD 119.33 1.97 1.62% |
President
Mr. Derek M. Davis is the Vice President Global Integration of the Company. He has responsibility for internal and external reporting planning and analysis and corporate and business unit accounting. From March 2006 to May 2007 he served as Director Financial Planning and Accounting. Prior to that he had served as Director Finance Operations and Logistics since December 2003. since 2021.
| Age | 51 |
| Tenure | 3 years |
| Address | 345 East Main Street, Warsaw, IN, United States, 46580 |
| Phone | 574 373 3333 |
| Web | https://www.zimmerbiomet.com |
Zimmer Biomet Management Efficiency
The company has Return on Asset of 0.044 % which means that on every $100 spent on assets, it made $0.044 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0836 %, implying that it generated $0.0836 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities. The Zimmer Biomet's current Return On Tangible Assets is estimated to increase to 0.18, while Return On Capital Employed is projected to decrease to 0.07. As of now, Zimmer Biomet's Fixed Asset Turnover is decreasing as compared to previous years. The Zimmer Biomet's current Asset Turnover is estimated to increase to 0.68, while Total Assets are projected to decrease to under 13.7 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Sherry Buck | Waters | 55 | |
| Henrik AncherJensen | Agilent Technologies | 59 | |
| Emily Hickey | Charles River Laboratories | N/A | |
| Birgit Girshick | Charles River Laboratories | 54 | |
| Susan Hardy | Charles River Laboratories | N/A | |
| Sanjay Chikarmane | Illumina | N/A | |
| Robert McMahon | Agilent Technologies | 55 | |
| Alan Malus | Thermo Fisher Scientific | 55 | |
| AmirAli Talasaz | Guardant Health | 44 | |
| Amol Chaubal | Waters | 47 | |
| Michael Boxer | Thermo Fisher Scientific | 58 | |
| Nancy Gillett | Charles River Laboratories | 58 | |
| Tristan Orpin | Illumina | 49 | |
| Michael Harrington | Waters | 59 | |
| Patrick Kaltenbach | Agilent Technologies | 53 | |
| Jonathan Seaton | Illumina | N/A | |
| Aimee Hoyt | Illumina | 47 | |
| Samraat Raha | Agilent Technologies | 51 | |
| Omead Ostadan | Illumina | 46 | |
| Sam Samad | Illumina | 48 | |
| Peter Hornstra | Thermo Fisher Scientific | 59 | |
Management Performance
| Return On Equity | 0.0836 | ||||
| Return On Asset | 0.044 |
Zimmer Biomet Holdings Leadership Team
Elected by the shareholders, the Zimmer Biomet's board of directors comprises two types of representatives: Zimmer Biomet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zimmer. The board's role is to monitor Zimmer Biomet's management team and ensure that shareholders' interests are well served. Zimmer Biomet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zimmer Biomet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sreelakshmi Kolli, Independent Director | ||
| Didier Deltort, President - Europe, Middle East and Africa | ||
| Carrie Nichol, Chief Accounting Officer, Vice President Controller | ||
| Arthur Higgins, Independent Director | ||
| Coleman Lannum, Senior Vice President - Investor Relations | ||
| Michael Michelson, Independent Director | ||
| Larry Glasscock, Independent Non-Executive Chairman of the Board | ||
| Nitin Goyal, Chief Science, Technology and Innovation Officer | ||
| Matt Abernethy, CPA, Vice President Investor Relations | ||
| Ellison Humphrey, Senior Vice President, Chief Transformation Officer | ||
| Daniel Florin, CFO, Senior Vice President | ||
| Robert Marshall, Vice President - Investor Relations, Treasurer | ||
| David Nolan, Group President of Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle and Bone Healing | ||
| Joseph Cucolo, President Americas | ||
| Derek Davis, Chief Accounting Officer, Vice President, Controller | ||
| Ivan Tornos, Group President - Global Businesses and Americas | ||
| Cecil Pickett, Independent Director | ||
| Angela Main, Global VP | ||
| Aure Bruneau, Group President Spine, CMF, Thoracic and Surgery Assisting Technology | ||
| Jeffrey Rhodes, Director | ||
| Wilfred Zuilen, President - Europe, Middle East and Africa | ||
| Katarzyna MazurHofsaess, President Europe, Middle East and Africa | ||
| Suketu Upadhyay, Chief Financial Officer, Executive Vice President | ||
| Paul Bisaro, Independent Director | ||
| Zeeshan Tariq, Senior Officer | ||
| Christopher Begley, Lead Independent Director | ||
| Bryan Hanson, Chairman of the Board, President, Chief Executive Officer | ||
| Sang Yi, President Asia Pacific | ||
| Betsy Bernard, Independent Director | ||
| Keri Mattox, Senior Vice President - Investor Relations, Chief Communications Officer | ||
| Adam Johnson, Group President Spine, Dental, CMF and Thoracic | ||
| Maria Hilado, Independent Director | ||
| Rachel Ellingson, Senior Vice President Chief Strategy Officer, Executive Officer | ||
| Daniel Williamson, Group President Joint Reconstruction | ||
| Nitin MD, Technology Science | ||
| Chad Phipps, Senior Vice President, General Counsel, Secretary | ||
| Syed Jafry, Independent Director | ||
| Paul Stellato, Controller VP | ||
| David Dvorak, CEO and President and Director | ||
| Michael Farrell, Independent Director | ||
| Tony Collins, Chief Accounting Officer, Vice President Controller | ||
| Lori Winkler, Chief Human Resource Officer, Senior Vice President | ||
| Zachary CPA, Director Relations | ||
| Gail Boudreaux, Independent Director | ||
| Stuart Kleopfer, President Americas | ||
| Robert Hagemann, Independent Director | ||
| Robert Delps, President Americas |
Zimmer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zimmer Biomet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0836 | ||||
| Return On Asset | 0.044 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 30.68 B | ||||
| Shares Outstanding | 205.46 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 90.97 % | ||||
| Number Of Shares Shorted | 4.73 M | ||||
| Price To Earning | 77.41 X |
Zimmer Biomet Investors Sentiment
The influence of Zimmer Biomet's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Zimmer. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Zimmer Biomet's public news can be used to forecast risks associated with an investment in Zimmer. The trend in average sentiment can be used to explain how an investor holding Zimmer can time the market purely based on public headlines and social activities around Zimmer Biomet Holdings. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Zimmer Biomet's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Zimmer Biomet's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Zimmer Biomet's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Zimmer Biomet.
Zimmer Biomet Implied Volatility | 31.67 |
Zimmer Biomet's implied volatility exposes the market's sentiment of Zimmer Biomet Holdings stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Zimmer Biomet's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Zimmer Biomet stock will not fluctuate a lot when Zimmer Biomet's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zimmer Biomet in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zimmer Biomet's short interest history, or implied volatility extrapolated from Zimmer Biomet options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Zimmer Biomet Holdings information on this page should be used as a complementary analysis to other Zimmer Biomet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Zimmer Stock analysis
When running Zimmer Biomet's price analysis, check to measure Zimmer Biomet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zimmer Biomet is operating at the current time. Most of Zimmer Biomet's value examination focuses on studying past and present price action to predict the probability of Zimmer Biomet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zimmer Biomet's price. Additionally, you may evaluate how the addition of Zimmer Biomet to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Zimmer Biomet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.16) | Dividend Share 0.96 | Earnings Share 4.88 | Revenue Per Share 35.43 | Quarterly Revenue Growth 0.063 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.